At a glance
ClinicalIndex Comparison RecordPhase 1Active· 60 enrolled
Drug / intervention
MK-3475drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
In Brief
A Phase 1 clinical trial evaluating MK-3475 for Brain Cancer. Active but no longer recruiting, targeting 60 participants across 7 sites.
Detailed Summary
This research study is studying an immunotherapy as a possible treatment for Glioblastoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 1Active
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartSep 2016
Primary CompletionJun 2022
TodayJul 2026
Study CompletionJul 2026
First PostedAug 2, 2016
Enrollment StartSep 21, 2016
Primary CompletionJun 2, 2022
Study CompletionJul 31, 2026
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 9.9 years ago
Interventions
MK-3475drug